This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Top ETFs of Last Week
by Sanghamitra Saha
Wall Street was moderately upbeat last week
3 Top-Ranked ETFs Under $20 for Your Portfolio
by Sweta Killa
Low-priced stocks could be attractive as these will enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. The Fed's plan to slower the balance sheet tightening process and the release of downbeat jobs data dragged down bond yields.
The Zacks Analyst Blog Highlights CRPT, WEED, SMH, CNCR and KBWP
by Zacks Equity Research
CRPT, WEED, SMH, CNCR and KBWP are part of the Zacks top Analyst Blog.
5 Market-Beating Sector ETFs of Q1
by Sweta Killa
Wall Street is set to wrap up the first quarter with strong gains. The gains were broad-based and well spread out across various segments.
Top & Flop ETF Areas of Wall Street's Best February in Decade
by Sanghamitra Saha
Wall Street surged to close out February with the S&P 500 and Nasdaq Composite notching their best February since 2015.
The Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKB
by Zacks Equity Research
CRPT, CNCR, WISE, AIRR and PKB are part of the Zacks top Analyst Blog.
5 Best-Performing Sector ETFs of February
by Sweta Killa
The gains were broad-based and well spread out across various segments. We have highlighted some of the top performers in the ETF space from different sectors of the market.
5 Sector ETFs Beating the Market Halfway Through Q1
by Sweta Killa
A combination of factors, including a solid earnings season, a resilient economy and a technology surge, powered the rally, resulting in a gain of about 5% for the S&P 500 Index this year.
5 ETF Areas That Spooked Investors in October
by Sanghamitra Saha
After a downbeat September, October too remained volatile for Wall Street due to higher rates.
Inside Tema ETFs' New Oncology ETF (CANC)
by Sanghamitra Saha
Oncology treatment has witnessed remarkable progress due to the relentless efforts of pharmaceutical companies in recent times.
Best & Worst Sector ETFs of First-Half 2023
by Sanghamitra Saha
These sector ETFs have won and lost the most in the first half of 2023.
5 Top-Ranked ETFs to Buy at Bargain Prices for 2023
by Sweta Killa
Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.
The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO
by Zacks Equity Research
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.
5 ETFs Riding High on the Biotech Comeback
by Sweta Killa
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Pharma & Biotech ETFs at One-Month High: Here's Why
by Sanghamitra Saha
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
Biotech ETFs Soars on Gilead-Immunomedics Deal
by Sweta Killa
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial
by Sweta Jaiswal, FRM
AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.
7 Top ETFs That Trumped Last Week's Market Rout
by Sanghamitra Saha
Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.
6 Sector ETFs Surviving the Market Rout
by Sweta Killa
Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.
5 ETFs Jump After Three-Day Rout: Will The Rally Last?
by Sweta Killa
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.